Recruiting
Biomarker Targeted Stimulation for Epileptiform Events
NCT06424977· Cadence Neuroscience· Source
Contact: Mariana Gallardo
Recruiting
A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants
NCT07727538· Phase 3· Ionis Pharmaceuticals, Inc.· Source
Contact: Ionis Pharmaceuticals, Inc.
Recruiting
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
NCT07586618· Phase 1· Allterum Therapeutics, Inc· Source
Contact: Heather Jernigan
Recruiting
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
NCT06900595· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kelly L. Vallance (principal investigator)
Recruiting
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source
Contact: Tiffany Skrodzi
Recruiting
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
NCT07112378· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Recruiting
A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
NCT07047144· Phase 2· Scholar Rock, Inc.· Source
Contact: Kayla Blough
Recruiting
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
NCT06317662· Phase 2· National Cancer Institute (NCI)· Source
Contact: Holly Pacenta (principal investigator)
Active, not recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125· Phase 3· Stoke Therapeutics, Inc· Source
Recruiting
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
NCT06124157· Phase 2· National Cancer Institute (NCI)· Source
Contact: Kenneth M. Heym (principal investigator)
Recruiting
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
NCT06401330· Phase 3· Children's Oncology Group· Source
Contact: Kelly L. Vallance (principal investigator)
Recruiting
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
NCT06647953· Phase 3· Children's Oncology Group· Source
Contact: Kelly L. Vallance (principal investigator)
Recruiting
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
NCT06513962· Phase 3· Children's Oncology Group· Source
Contact: Karen H. Albritton (principal investigator)
Recruiting
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
NCT06450041· Phase 2· New Approaches to Neuroblastoma Therapy Consortium· Source
Contact: Chelsee Greer, DO
Recruiting
A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study
NCT06410209· Phase 2· Children's Oncology Group· Source
Contact: Donald T. Beam (principal investigator)
Recruiting
A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators
NCT06504589· Nicole Hamblett· Source
Contact: Anna Reyes
Recruiting
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
NCT05711667· Phase 3· Children's Oncology Group· Source
Contact: Richard P. Howrey (principal investigator)
Recruiting
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
NCT06064097· Phase 2· National Cancer Institute (NCI)· Source
Contact: Chelsee Greer (principal investigator)
Recruiting
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
NCT06056297· Phase 3· X4 Pharmaceuticals· Source
Contact: Patient Affairs and Advocacy
Recruiting
A Clinical Study to Evaluate the Safety and Efficacy of ETX101 in Infants and Children With SCN1A-Positive Dravet Syndrome
NCT05419492· Phase 1/2· Encoded Therapeutics· Source
Contact: Neurology Epilepsy Research
Recruiting
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
NCT06172296· Phase 3· National Cancer Institute (NCI)· Source
Contact: Chelsee Greer (principal investigator)
Recruiting
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067· Phase 1· St. Jude Children's Research Hospital· Source
Contact: Holly Pacenta, MD
Recruiting
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
NCT05509777· Phase 3· Eli Lilly and Company· Source
Contact: Clifton Huang (principal investigator)
Recruiting
Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease
NCT06023641· Phase 2· St. Jude Children's Research Hospital· Source
Contact: Karen Albritton, MD
Active, not recruiting
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171· Phase 2· Children's Oncology Group· Source
Recruiting
A Study to Learn More About the Health of Persons With Down Syndrome After Treatment for Acute Leukemia
NCT05702645· Children's Oncology Group· Source
Contact: Donald T. Beam (principal investigator)
Active, not recruiting
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194· Phase 3· Children's Oncology Group· Source
Recruiting
A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma
NCT05705531· Children's Oncology Group· Source
Contact: Donald T. Beam (principal investigator)
Recruiting
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
NCT05865301· Stanford University· Source
Contact: Holly Pacenta
Recruiting
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410· Phase 3· National Cancer Institute (NCI)· Source
Contact: Karen H. Albritton (principal investigator)
Recruiting
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study
NCT05548283· Phase 4· Chris Goss· Source
Contact: Jill Finto
Active, not recruiting
Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome
NCT05457556· Phase 3· Children's Oncology Group· Source
Active, not recruiting
ABTECT - Maintenance
NCT05535946· Phase 3· Abivax S.A.· Source
Recruiting
Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
NCT05535166· Phase 2· St. Jude Children's Research Hospital· Source
Contact: Sibo Zhao, MD
Recruiting
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126· Phase 2· Pfizer· Source
Active, not recruiting
Rapid Administration Pilot for Infusing Dinutuximab
NCT05421897· Phase 2· Children's Hospital Los Angeles· Source
Active, not recruiting
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
NCT05286801· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Vincristine Pharmacokinetics in Infants
NCT05359237· Children's Oncology Group· Source
Active, not recruiting
A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX)
NCT05540860· Phase 2· Edgewise Therapeutics, Inc.· Source
Recruiting
GABA Biomarkers in Dravet Syndrome
NCT05651204· Cook Children's Health Care System· Source
Contact: Sabrina Shandley, PhD
Active, not recruiting
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow
NCT05330325· Phase 3· Novo Nordisk A/S· Source
Recruiting
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
NCT05304585· Phase 3· Children's Oncology Group· Source
Contact: Kelly L. Vallance (principal investigator)
Active, not recruiting
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
NCT05099003· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor
NCT04939597· Phase 3· Children's Oncology Group· Source
Recruiting
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
NCT04726241· Phase 1/2· PedAL BCU, LLC· Source
Contact: Holly Pacenta (principal investigator)
Recruiting
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
NCT05235165· Phase 3· Children's Oncology Group· Source
Contact: Karen H. Albritton (principal investigator)
Recruiting
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944· Phase 1/2· Children's Oncology Group· Source
Contact: Sibo Zhao (principal investigator)
Active, not recruiting
Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors
NCT05071209· Phase 1/2· National Cancer Institute (NCI)· Source
Active, not recruiting
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT04898894· Phase 1· St. Jude Children's Research Hospital· Source
Recruiting
Robot-assisted Training in Children With CP
NCT06450158· Cook Children's Health Care System· Source
Contact: Sadra Shahdadian, PhD
Showing 50 of 102.